Is Disc Medicine Inc. Common Stock a good investment? Disc Medicine Inc. Common Stock (IRON) is currently trading at 59.87 USD. Market analysts have a consensus price target of 99.73 USD. This suggests a potential upside from current levels.
Earnings Schedule: Disc Medicine Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -5.26.
No, it does not currently pay a dividend.
Disc Medicine Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -4.46.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 30, 2022 | 0.030000 |
Community Discussion